Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of ALLEXTEN vs BILAXTEN 20 mg Tablets in Healthy Thai Volunteers
TCTR20251206001Phase 1Not yet recruiting
- Sponsor
- International Bio Service
- Start
- Jan 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in allergic rhinitis (AR) and urticaria (2 arms), sponsored by International Bio Service. Primary endpoint: Primary pharmacokinetic bioequivalence endpoints. Planned start Jan 2026; status: not yet recruiting.
02
Conditions
allergic rhinitis (AR)urticaria
Beyond the preview
Go deeper on TCTR20251206001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20251206001.